medigraphic.com

2016, Number 1

<< Back Next >>

Rev Cuba Endoc 2016; 27 (1)

Clinical, hormonal and echographic correspondence in the diagnosis of polycystic ovary syndrome

Vázquez NJC, Calero RJL, Carías JP, Monteagudo PG

Language: Spanish
References: 45
Page: 4-17
PDF size: 210.27 Kb.


ABSTRACT

Introduction: polycystic ovary syndrome is the most common endocrine disorder in a woman at reproductive age. It is characterized by menstrual disorders, hyperandrogenism and CT-detected polycystic ovaries and it has an effect on fertility and metabolism.
Objective: to determine the frequency of occurrence of diagnostic criteria of polycystic ovary syndrome in women suspected of suffering this disease, and the possible correspondence among the clinical, hormonal and echographic diagnoses.
Methods: a correlational descriptive study was conducted in 140 women. They were questioned and physically examined in addition to performing diagnostic ultrasound and study of the follicle-stimulating hormone, the luteinizing hormone and testosterone. For the statistical analysis, the frequency tables and the Chi square test (p ‹ 0.05) were used.
Results: the average age was 26.3 years. Of 96 women (68.5 %) with menstrual disorders, 76 (79.2 %) said they had oligomenorrhea. Sixty four were overweighed (45.7 %). Elevated testosterone was the predominant hormonal alteration (52.7 %). In the group, the ovary volume was equal to or higher than 10cc in 84.3 % of the group. Significant association was observed between the menstrual disorders and the presence of polycystic ovaries (p= 0.000), hirsutism (p= 0.001) and acne (p= 0.000), but this did not occur with the hormonal variables. The echographic diagnosis and the elevated testosterone showed correspondence in 46.2 % of patients.
Conclusions: there is association between the clinical variables and the diagnoses of polycystic ovary syndrome, but neither the echographic and hormonal diagnostic criteria, nor the hormonal alterations and the clinical and echographic diagnosis of polycystic ovary syndrome were related.


REFERENCES

  1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1-13.

  2. Azziz R. Position statement: criteria for defining polycystic ovary syndrome as predominantly hyperandrogenic syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006;91:4237-45.

  3. Diamanti-Kandarakis E, Kouli C, Bergiele A, Filandra F, Tsianateli T, Spina G, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006-11.

  4. Mahesh VB. Hirsutism, virilism, polycystic ovarian disease, and the steroidgonadotropin- feedback system: a career retrospective. Am J Physiol Endocrinol Metab. 2012;302(1):E4-E18.

  5. Álvarez F. Prevalencia del síndrome del ovario poliquístico y de factores de riesgo cardiovascular en mujeres obesas premenopáusicas [tesis doctoral]. Universidad de Alcalá, Madrid; 2009.

  6. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.

  7. Tehrani FR, Rashidi H, Khomami MB, Tohidi M, Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014;12(1):89.

  8. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol. 2013;5;373(0):29-38.

  9. Serdar EB. Fisiología y patología del eje reproductor femenino. En: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Tratado de Endocrinología de Williams. Madrid: Elsevier; 2009. p. 569-89.

  10. Hayes FJ. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics. J Clin Endocrinol Metab. 1998;83(7):2343-9.

  11. Hirschberg AL. Polycystic Ovary Syndrome, Obesity and Reproductive Implications [homepage en Internet] [citado 24 de agosto de 2010]. Disponible en: http://cme.medscape.com/viewarticle/707476

  12. Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Arch Gynecol Obstet. 2006;274(4):187-97.

  13. ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19-25.

  14. The Rotterdam ESHRE/ASRM-sponsored PCOS. Consensus Workshop Group Revised 2003. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.

  15. Ahmed S, Pahwa S, Das CJ, Mir FA, Nisar S, Jehangir M, et al. Comparative evaluation of sonographic ovarian morphology of Indian women with polycystic ovary syndrome versus those of normal women. Indian J Endocrinol Metab. 2014;18(2):180-4.

  16. Pacheco J. Manejo del síndrome de ovario poliquístico en la mujer infértil. Rev Per Ginecol Obstet. 2008;54:143-8.

  17. Oliva-Rodríguez JA. Diagnóstico ultrasonográfico de las afecciones ováricas. En: Oliva-Rodríguez JA, ed. Ultrasonografía diagnóstica fetal, obstétrica y ginecológica. La Habana: Editorial Ciencias Médicas; 2009. p. 351.

  18. Slowey MJ. Polycystic Ovary Syndrome: New Perspective on an Old Problem. South Med J. 2001;94(2):190-6.

  19. Iturra A. Síndrome de ovario poliquístico y la evaluación ultrasonográfica en la práctica diaria. Rev Chil Ultrasonog. 2008;11:18-21.

  20. García Y, Monteagudo G, Padrón RS, González R. Evaluación de la sensibilidad a la insulina en el síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2009;20(3):131-40.

  21. García Y, Monteagudo G, Padrón RS, González R. Evaluación de las alteraciones lipídicas en el síndrome de ovarios poliquísticos y su relación con la resistencia a la insulina. Rev Cubana Endocrinol. 2010;21(2):145-53.

  22. Ovies G, Domínguez E, Verdeja OL, Zamora H. Frecuencia y características clínicas, hormonales y ultrasonográficas sugestivas de síndrome de ovarios poliquísticos en un grupo de mujeres con síndrome metabólico. Rev Cubana Endocrinol [serie en Internet]. 2008 [citado 8 de octubre de 2012];19(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532008000100004&lng=es&nrm=iso&tlng=es

  23. Ovies G, Domínguez E, Verdeja OL, Zamora H. Asociación entre variables hormonales y clínicas y el resultado del ultrasonido ginecológico en mujeres con síndrome metabólico. Rev Cubana Endocrinol [serie en Internet]. 2008 [citado 8 de octubre de 2012];19(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532008000200003&lng=es&nrm=iso&tlng=es

  24. Ovies G, Martínez A, Monteagudo G, Sardiñas I. Bases genéticas del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol. 2011;22(3):255-65.

  25. Acosta A, Monteagudo G, Menocal A. Patrón hormonal de mujeres con diagnóstico clínico y ecográfico del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol [serie en Internet]. 2004 [citado 8 de octubre de 2012];15(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532004000200003&lng=es&nrm=iso&tlng=es

  26. Klein S. Obesidad. En: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Tratado de Endocrinología de Williams. Madrid: Elsevier; 2009. p. 1579.

  27. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181-91.

  28. Guo M, Chen Z, Eijkemans M, Goverde A, Fauser B, Macklon N. Comparison of the phenotype of Chinese versus Dutch Caucasian women presenting with polycystic ovary syndrome and oligo/amenorrhoea. Hum Reprod. 2012;27(5):1481-8.

  29. Motta A. Report of the international symposium: polycystic ovary syndrome: first Latin-American consensus. International Journal of Clinical Practice. 2010;64:544-57.

  30. Brassard M, Baillargeon J. Basic infertility including polycystic ovary syndrome. Med Clin North Am. 2008;92:1163-92.

  31. Johnstone EB, Rosen MP, Neril R, Trevithick D, Sternfeld B, Murphy R, et al. The Polycystic Ovary Post-Rotterdam: A Common, Age-Dependent Finding in Ovulatory Women without Metabolic Significance. J Clin Endocrinol Metab. 2010;95(11):4965-72.

  32. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine. 2010;8:41-7.

  33. Pedersen SD, Brar S, Faris P, Corenblum B. Polycystic ovary syndrome. Validated questionnaire for use in diagnosis. Can Fam Physician. 2007;53:1041-7.

  34. Moran C, Tena G, Preciado R, Ruiz P, Reyna R, Moran S. Prevalence of polycystic ovary syndrome in Mexican women. Gynecol Obstet Invest. 2010;69(4):274-80.

  35. Fábregues-Gasol F. Epidemiología y conceptos generales. En: Checa-Vizcaíno MA, Espinós-Gómez JJ, Matorras-Weining R, eds. Síndrome del ovario poliquístico. Madrid: Médica Panamericana; 2006. p. 13-24.

  36. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010 October;122(0):10.

  37. Guastella E, Longo RA, Carmina E. Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril. 2010;94(6):2197-201.

  38. Builes CA, Diaz I, Castañeda J, Perez LE. Caracterización clínica y bioquímica de la mujer con Síndrome del ovario poliquístico. Rev Colombiana Obstet Ginecol. 2006;57(1):36-44.

  39. Vargas M, Sánchez G, Herrera J. Síndrome de ovarios poliquísticos: abordaje diagnóstico y terapéutico. Rev Biomed. 2003;14:191-203.

  40. Lerchbaum E, Schwetz V, Giuliani A, Pieber TR, Obermayer-Pietsch B. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril. 2012 Nov;98(5):1318-25.

  41. Golbahar J, Al-Ayadhi M, Das NM, Gumaa K. Sensitive and specific markers for insulin resistance, hyperandrogenemia, and inappropriate gonadotrophin secretion in women with polycystic ovary syndrome: a case-control study from Bahrain. Int J Womens Health. 2012;4:201-6.

  42. Kar S. Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: A prospective study of PCOS women. J Hum Reprod Sci. 2013;6(3):194-200.

  43. Franks S. Controversy in clinical endocrinology. Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clinical Endocrinol Metab. 2006;91:786-9.

  44. Carvajal R, Herrera C, Porcile A. Espectro fenotípico del síndrome de ovario poliquístico. Rev Chil Obstet Ginecol. 2010;75(2):124-32.

  45. Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J Endocrinol Metab. 2012;16(6): 996-9.




2020     |     www.medigraphic.com